Fenemal "DLF" 100 mg tabletter Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

fenemal "dlf" 100 mg tabletter

dansk lægemiddelforsyning dlf aps - phenobarbital - tabletter - 100 mg

Testosteron "Medical Valley" 1000 mg/4 ml injektionsvæske, opløsning Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

testosteron "medical valley" 1000 mg/4 ml injektionsvæske, opløsning

medical valley invest ab - testosteronundecanoat - injektionsvæske, opløsning - 1000 mg/4 ml

Orfiril Long 1000 mg depotgranulat Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

orfiril long 1000 mg depotgranulat

desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 1000 mg

Basocare 1000 mg enterotabletter Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

basocare 1000 mg enterotabletter

fresenius medical care deutschland gmbh - natriumhydrogencarbonat - enterotabletter - 1000 mg

Oroxine 100 mikrogram tabletter Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

oroxine 100 mikrogram tabletter

aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 100 mikrogram

Xtandi Eiropas Savienība - dāņu - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Erleada Eiropas Savienība - dāņu - EMA (European Medicines Agency)

erleada

janssen-cilag international nv - apalutamide - prostatiske neoplasmer - endokrine terapi - erleada er anført:i voksne mænd til behandling af ikke-metastatisk kastration resistent prostatakræft (nmcrpc), som er i høj risiko for at udvikle metastatisk sygdom. hos voksne mænd til behandling af metastatisk hormon-følsomme prostatakræft (mhspc) i kombination med androgen deprivation terapi (adt).